The merger between Peptonic and Pharmiva creates a leading global femtech company
At an extraordinary general meeting on August 21, Pharmiva's shareholders approved the planned merger between Peptonic Medical AB (“Peptonic”) and Pharmiva AB (“Pharmiva”). The merger creates a stronger player in the rapidly growing market for intimate women's health.The decision at the extraordinary general meeting means that the merger is expected to be completed during the fourth quarter of 2023, in accordance with the communicated schedule. ”The merger with Pharmiva is strategically important and means that we immediately strengthen our product portfolio and increase the pace in
